GlcNAcstatinSelective O-GlcNAcase inhibitor CAS# 922163-64-2 |
2D Structure
- Mycophenolate Mofetil
Catalog No.:BCC2290
CAS No.:128794-94-5
- AGI-5198
Catalog No.:BCC2293
CAS No.:1355326-35-0
- Trilostane
Catalog No.:BCC2302
CAS No.:13647-35-3
- AGI-6780
Catalog No.:BCC1331
CAS No.:1432660-47-3
- CPI-613
Catalog No.:BCC2287
CAS No.:95809-78-2
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 922163-64-2 | SDF | Download SDF |
PubChem ID | 122173013 | Appearance | Powder |
Formula | C20H27N3O4 | M.Wt | 373.45 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in DMSO | ||
Chemical Name | N-[(5S,6R,7R,8R)-6,7-dihydroxy-5-(hydroxymethyl)-2-(2-phenylethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-8-yl]-2-methylpropanamide | ||
SMILES | CC(C)C(=O)NC1C(C(C(N2C1=NC(=C2)CCC3=CC=CC=C3)CO)O)O | ||
Standard InChIKey | YCPLHXLUOSXDJD-WNRNVDISSA-N | ||
Standard InChI | InChI=1S/C20H27N3O4/c1-12(2)20(27)22-16-18(26)17(25)15(11-24)23-10-14(21-19(16)23)9-8-13-6-4-3-5-7-13/h3-7,10,12,15-18,24-26H,8-9,11H2,1-2H3,(H,22,27)/t15-,16-,17+,18+/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | GlcNAcstatin is a selective inhibitor of O-GlcNAcase (OGA) with Ki of 4.6 pM. | |||||
Targets | OGA | |||||
IC50 | 4.6 pM (Ki) |
GlcNAcstatin Dilution Calculator
GlcNAcstatin Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.6777 mL | 13.3887 mL | 26.7773 mL | 53.5547 mL | 66.9434 mL |
5 mM | 0.5355 mL | 2.6777 mL | 5.3555 mL | 10.7109 mL | 13.3887 mL |
10 mM | 0.2678 mL | 1.3389 mL | 2.6777 mL | 5.3555 mL | 6.6943 mL |
50 mM | 0.0536 mL | 0.2678 mL | 0.5355 mL | 1.0711 mL | 1.3389 mL |
100 mM | 0.0268 mL | 0.1339 mL | 0.2678 mL | 0.5355 mL | 0.6694 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
GlcNAcstatin is a highly potent and competitive inhibitor of O-GlcNAcase (OGA) with Ki value of 4.4 nM for human OGA [1].
GlcNAcstatin is a synthetic GlcNAc-configured nagstatin derivative with a larger isobutanamido group on N8 and a phenethyl group on C2. It inhibited bacterial OGA with Ki value of 4.6 pM. For human OGA, GlcNAcstatin also showed a potent inhibition with Ki value of 4.4 nM. Besides that, GlcNAcstatin exerted inhibitory activity against human lysosomal Hex A/B with Ki value of 550 nM, suggesting that it is a selective inhibitor of OGA. In HEK293 cells, treatment of GlcNAcstatin at concentration of 20 nM resulted in increased cellular O-GlcNAc levels of many proteins. GlcNAcstatin also significantly prevented O-GlcNAc from binding to proteins in SH-SY5Y human neuroblastoma cell lysates [1, 2].
References:
[1] Dorfmueller H, Borodkin V, Schimpl M, et al. GlcNAcstatins are nanomolar inhibitors of human O-GlcNAcase inducing cellular hyper-O-GlcNAcylation. Biochem. J, 2009, 420: 221-227.
[2] Dorfmueller H C, Borodkin V S, Schimpl M, et al. GlcNAcstatin: a picomolar, selective O-GlcNAcase inhibitor that modulates intracellular O-glcNAcylation levels. Journal of the American Chemical Society, 2006, 128(51): 16484-16485.
- SCH 529074
Catalog No.:BCC6131
CAS No.:922150-11-6
- 12-O-Tiglylphorbol-13-isobutyrate
Catalog No.:BCN2512
CAS No.:92214-54-5
- Phosphocreatine disodium salt
Catalog No.:BCC7918
CAS No.:922-32-7
- Capecitabine-2',3'-cyclic carbonate
Catalog No.:BCC8903
CAS No.:921769-65-5
- Neuromedin N (rat, mouse, porcine, canine)
Catalog No.:BCC5840
CAS No.:92169-45-4
- Cysteine Protease inhibitor
Catalog No.:BCC5301
CAS No.:921625-62-9
- Fmoc-D-Lys(Boc)-OH
Catalog No.:BCC3526
CAS No.:92122-45-7
- ent-16-Kaurene-3beta,15beta,18-triol
Catalog No.:BCN6624
CAS No.:921211-29-2
- 4'-Methoxypuerarin
Catalog No.:BCN2901
CAS No.:92117-94-7
- Schisanlactone C
Catalog No.:BCN3314
CAS No.:92051-27-9
- Schisanlactone D
Catalog No.:BCN3247
CAS No.:92051-26-8
- Tenacigenoside A
Catalog No.:BCN4458
CAS No.:920502-42-7
- 5,6-Desmethylenedioxy-5-methoxyaglalactone
Catalog No.:BCN7639
CAS No.:922169-96-8
- Syringin pentaacetate
Catalog No.:BCN4459
CAS No.:92233-55-1
- Daphnilongeridine
Catalog No.:BCN4460
CAS No.:922522-15-4
- (±)-MDMA hydrochloride
Catalog No.:BCC5965
CAS No.:92279-84-0
- Sanggenon N
Catalog No.:BCN4846
CAS No.:92280-12-1
- 3-O-Methyl-3-methoxymaxterone
Catalog No.:BCC8639
CAS No.:92282-70-7
- Refametinib
Catalog No.:BCC4276
CAS No.:923032-37-5
- Refametinib R enantiomer
Catalog No.:BCC4055
CAS No.:923032-38-6
- SAR407899 hydrochloride
Catalog No.:BCC5592
CAS No.:923262-96-8
- Opicapone
Catalog No.:BCC6545
CAS No.:923287-50-7
- Nilotinib monohydrochloride monohydrate
Catalog No.:BCC1801
CAS No.:923288-90-8
- SAR407899
Catalog No.:BCC5593
CAS No.:923359-38-0
Protein-ligand interaction study of CpOGA in complex with GlcNAcstatin.[Pubmed:23066949]
Chem Biol Drug Des. 2013 Feb;81(2):284-90.
The GlcNAcstatin is a potent inhibitor of O-glycoprotein 2-acetamino-2-deoxy-beta-D-glucopyranosidase, which has been related with type II diabetes and neurodegenerative disorders. Herein, hybrid quantum mechanics/molecular mechanics, molecular dynamics simulations, and potential of mean force were employed to study the interactions established between GlcNAcstatin and a bacterial O-GlcNAcase enzyme from Clostridium perfringens. The results reveal that the imidazole nitrogen atom of GlcNAcstatin has shown a better interaction with the active site of Clostridium perfringens in its protonated form, which is compatible with a substrate-assisted reaction mechanism involving two conserved aspartate residues (297 and 298). Furthermore, the quantum mechanics/molecular mechanics-molecular dynamics simulations appointed a strong interaction between Asp401, Asp298, and Asp297 residues and the GlcNAcstatin inhibitor, which is in accordance with experimental data. Lastly, these results may contribute to understand the molecular mechanism of inhibition of Clostridium perfringens by GlcNAcstatin inhibitor and, consequently, this study might be useful to design new molecules with more interesting inhibitory activity.
GlcNAcstatin: a picomolar, selective O-GlcNAcase inhibitor that modulates intracellular O-glcNAcylation levels.[Pubmed:17177381]
J Am Chem Soc. 2006 Dec 27;128(51):16484-5.
Many phosphorylation signal transduction pathways in the eukaryotic cell are modulated by posttranslational modification of specific serines/threonines with N-acetylglucosamine (O-GlcNAc). Levels of O-GlcNAc on key proteins regulate biological processes as diverse as the cell cycle, insulin signaling, and protein degradation. The two enzymes involved in this dynamic and abundant modification are the O-GlcNAc transferase and O-GlcNAcase. Structural data have recently revealed that the O-GlcNAcase possesses an active site with significant structural similarity to that of the human lysosomal hexosaminidases HexA/HexB. PUGNAc, an O-GlcNAcase inhibitor widely used to raise levels of O-GlcNAc in human cell lines, also inhibits these hexosaminidases. Here, we have exploited recent structural information of an O-GlcNAcase-PUGNAc complex to design and synthesize a glucoimidazole-based inhibitor, GlcNAcstatin, which is a 5 pM competitive inhibitor of enzymes of the O-GlcNAcase family, shows 100000-fold selectivity over HexA/B, and binds to the O-GlcNAcase active site by mimicking the transition state as revealed by X-ray crystallography. This compound is able to raise O-GlcNAc levels in human HEK 293 and SH-SY5Y neuroblastoma cell lines and thus provides a novel, potent tool for the study of the role of O-GlcNAc in intracellular signal transduction pathways.